Voluntary announcement - phase iii clinical trial of docetaxel for injection (albumin-bound) (HB1801) for the treatment of advanced breast cancer officially initiated in china
Filed with HKEX · Stock code 1093 ·
6ix hasn’t read this filing yet.
CSPC Pharmaceutical Group Limited on 6ix
Earlier from CSPC Pharmaceutical
- Notification letter to shareholder and change request form
- Notification letter to non-registered holder and request form
- Letter to new registered shareholders and reply form
- 2026 Interim report
- Voluntary announcement - phase ii clinical trial of SYH2069 injection for the treatment of type 2 diabetes mellitus in adult patients officially initiated at the first centre in china
Later from CSPC Pharmaceutical
- Voluntary announcement - phase iii clinical trial of becotatug (JMT101) in combination with osimertinib for the first-line treatment of locally advanced or metastatic nsclc harbouring egfr exon 20 insertion mutations achieves positive topline results
- Voluntary announcement - SYS6077 injection obtains clinical trial approval in china
- Voluntary announcement - recombinant herpes zoster vaccine (SYS6052) obtains clinical trial approval in the U.S.
- Voluntary announcement - phase ib clinical trial of JMT206 injection for weight management in adult patients with overweight or obesity officially initiated at the first study centre in china
- Voluntary announcement - results of phase iii clinical study of efmedaglutide alfa injection in combination with metformin in chinese adult patients with type 2 diabetes mellitus presented in a short oral discussion at the 62nd annual meeting of the european association for the study of diabetes (easd 2026)
Follow CSPC Pharmaceutical into a list and get an email when it puts out news.
Follow CSPC Pharmaceutical